Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose escalation study of adalimumab in Japanese Crohn's disease patients with loss of response
2015-004121-13Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc. Primary endpoint: Clinical response-50 at Week 8.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-004121-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004121-13.